#United States #New York #Levi & Korsinsky #Securities Class Action #Regencell Bioscience

Regencell Bioscience Holdings: An Urgent Call to Investors

In a recent announcement, Levi & Korsinsky, LLP, a law firm that specializes in shareholder rights, has issued a vital reminder for investors in Regencell Bioscience Holdings Limited (NASDAQ: RGC). A securities class action lawsuit has been filed against the company, affecting shareholders who purchased securities between October 28, 2024 and October 31, 2025. The deadline for investors to apply as lead plaintiffs in this class-action suit is June 23, 2026.

Background of the Case

This case emerged following a significant drop in Regencell's stock price after the company disclosed it had received a subpoena from the U.S. Department of Justice (DOJ) related to trading activities. Specifically, RGC shares plummeted by $3.09, or approximately 18.56%, closing at $13.56 on November 3, 2025. This revelation has left many investors facing substantial financial losses, prompting the legal action.

Regencell is an early-stage bioscience company that, despite having no approved products or revenue, saw its market capitalization soar to nearly $14 billion at one point. This valuation has raised eyebrows and questions about the legitimacy of its market position. Notably, only a small fraction of companies in the Nasdaq Biotechnology Index had comparably high valuations, raising suspicions about potential market manipulation.

Allegations of Securities Fraud

The class action lawsuit alleges that Regencell's share price experienced massive fluctuations that had no basis in its actual business performance. For instance, RGC stocks skyrocketed from under $0.30 to a high of $78.00 per share within the class period—a staggering 48,650% increase—despite no significant business developments justifying such a surge.

The complaint further contends that defendants were aware or at least negligent regarding the company's vulnerability to market manipulation. They reportedly failed to disclose critical information about potential risks, thus misleading investors during a period of extreme volatility influenced by external speculations and trading motivations.

Market Manipulation Risks and Implications

Key aspects of the lawsuit highlight several crucial points:

• - Regencell's stock exhibited extreme price and volume fluctuations unrelated to its operational performance.
• - The company itself acknowledged that developing new medical products typically requires investments in the range of $4 billion to $10 billion, while its annual research and development budget stood at only $1 million.
• - A staggering 88.6% of outstanding shares were controlled by a single insider, the company's founder, which potentially created a market environment ripe for manipulation.
• - Despite these alarming indicators, the company attributed its price volatility primarily to short-selling activities and external media reports, choosing not to address the possibility of internal manipulation.

As a result of the investigation, Regencell has also acknowledged the likelihood of incurring penalties and costs associated with potential legal outcomes, putting countless shareholders in precarious financial situations. The firm’s massive growth in value without sufficient business fundamentals raises critical questions about how market integrity is maintained, especially in sectors as delicate as bioscience.

Next Steps for Investors

Investors who purchased Regencell stocks during the specified period and incurred losses may have the opportunity to participate in this class action. It is advisable for affected investors to gather relevant documents, such as brokerage records detailing their purchase dates, shares bought, and prices paid. For those interested in joining the lawsuit or seeking more information, contacting Levi & Korsinsky for a free consultation may be a prudent first step.

Joseph E. Levi, Esq., who is leading the case, stated, “This lawsuit seeks to hold accountable those who have put shareholders at risk through poor disclosures and potential market manipulation.”

It’s essential for shareholders to understand their rights and options in this ongoing legal matter and adhere to upcoming deadlines to ensure their voices are heard in the pursuit of justice.